FDA Enforcement Letters On Rx Drug Promotions Plummet In 2013
This article was originally published in The Pink Sheet Daily
OPDP Director Tom Abrams cautions against reading into the “snapshot.”
You may also be interested in...
US agency disagrees that study of consumer and healthcare professional ability to detect deceptive promos is unnecessary; final guidance on product name placement in labeling and advertisements mirrors 2013 draft.
Even with recent letters, Office of Prescription Drug Promotion’s slow pace continues from 2014’s record low.
Office of Prescription Drug Promotion issues 23 letters in 2013, five less than the previous year.